Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

IQ-AI (IQAI) Share Price

Price 0.84p on 31-03-2025 at 16:30:03
Change -0.02p -2.33%
Buy 0.85p
Sell 0.83p
Buy / Sell IQAI Shares
Add to Watchlist
Add to Portfolio
Add to Quickpicks
Last Trade: Buy 900.00 at 0.846p
Day's Volume: 769,407
Last Close: 0.84p
Open: 0.86p
ISIN: JE00BD4H0R42
Day's Range 0.80p - 0.86p
52wk Range: 0.80p - 2.00p
Market Capitalisation: £2m
VWAP: 0.843425p
Shares in Issue: 247m

Sector: Health Care and Related Services

IQ-AI (IQAI) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 900 0.846p Ordinary
 12:12:14 - 31-Mar-25
Buy* 50,567 0.846p Ordinary
 11:36:06 - 31-Mar-25
Buy* 280 0.85p SI Trade
 11:13:24 - 31-Mar-25
Buy* 3,176 0.85p SI Trade
 11:13:24 - 31-Mar-25
Buy* 14,820 0.85p SI Trade
 11:13:24 - 31-Mar-25
Buy* 10,712 0.85p SI Trade
 11:13:24 - 31-Mar-25
Buy* 15,000 0.85p SI Trade
 11:13:24 - 31-Mar-25
Sell* 150,000 0.85p Ordinary
 11:13:19 - 31-Mar-25
Sell* 150,000 0.85p Ordinary
 11:12:38 - 31-Mar-25
Sell* 150,000 0.85p Ordinary
 11:11:31 - 31-Mar-25
See more IQ-AI trades

IQ-AI (IQAI) Share Price History

Time period:
to
Date Open High Low Close Volume
31st Mar 2025 (Mon) 0.86 0.86 0.80 0.84 769,407
28th Mar 2025 (Fri) 0.94 0.86 0.85 0.86 1,902,808
27th Mar 2025 (Thu) 0.94 0.94 0.94 0.94 0
26th Mar 2025 (Wed) 0.94 0.94 0.94 0.94 164,913
25th Mar 2025 (Tue) 0.94 0.94 0.94 0.94 70,272
24th Mar 2025 (Mon) 0.925 0.94 0.925 0.94 30,485
21st Mar 2025 (Fri) 0.96 0.97 0.97 0.97 290,894
20th Mar 2025 (Thu) 0.96 0.96 0.96 0.96 1,067,612
19th Mar 2025 (Wed) 1.00 1.00 0.96 0.96 2,825,628
18th Mar 2025 (Tue) 1.40 1.40 0.975 0.975 3,884,468
17th Mar 2025 (Mon) 1.40 1.40 1.40 1.40 0
14th Mar 2025 (Fri) 1.40 1.40 1.40 1.40 13,674
13th Mar 2025 (Thu) 1.35 1.40 1.35 1.40 432,404
12th Mar 2025 (Wed) 1.35 1.35 1.35 1.35 75,000
11th Mar 2025 (Tue) 1.40 1.40 1.35 1.35 65,828
10th Mar 2025 (Mon) 1.40 1.40 1.40 1.40 121,565
7th Mar 2025 (Fri) 1.40 1.40 1.40 1.40 95,000
6th Mar 2025 (Thu) 1.40 1.40 1.40 1.40 114,471
5th Mar 2025 (Wed) 1.40 1.40 1.30 1.40 321,791
4th Mar 2025 (Tue) 1.40 1.40 1.40 1.40 114,248
3rd Mar 2025 (Mon) 1.40 1.40 1.40 1.40 42,859
See more IQ-AI price history

IQ-AI (IQAI) Regulatory News

Date Source Headline
18th Mar 2025 10:38 am RNS Placing to raise £250,000
3rd Feb 2025 7:00 am RNS IB Expands Distribution with Blackford
22nd Jan 2025 7:00 am RNS Operations Update
10th Jan 2025 7:49 am RNS IB and Prism Secure First Installation
20th Nov 2024 7:00 am RNS Imaging Biometrics Expands Distribution
19th Nov 2024 11:27 am RNS Board Changes
5th Nov 2024 7:00 am RNS New Patent Application and Trading Update
15th Oct 2024 10:28 am RNS Holding(s) in Company
14th Oct 2024 12:08 pm RNS Holding(s) in Company
14th Oct 2024 12:05 pm RNS PDMR dealing and TR1 announcement
See more IQ-AI regulatory news

IQ-AI (IQAI) Share News

IN BRIEF: IQ-AI amends distribution deal with Blackford Analysis

3rd Feb 2025 19:22

IQ-AI Ltd - London-based medical services company - Amends existing distribution agreement with artificial intelligence platform provider Blackford Analysis Ltd. The amendment adds IB Nimble, IB ASL, IB FTB, and IB FTB Express to the agreement, allowing Blackford to also sell these products to their global client base. Acquired by Bayer in early 2023, Blackford operates in the healthcare AI platform and solutions sphere. Read More

IN BRIEF: IQ-AI to take GaM to phase II study, flags AI capabilities

22nd Jan 2025 17:10

IQ-AI Ltd - London-based medical services company - Provides operations update focusing on artificial intelligence. Explains radiology leads the way in Food & Drug Administration approvals for AI-enabled products as the FDA has increased efforts to keep pace with the advancements in AI technology. The company believes its subsidiary, Imaging Biometrics LLC, is in a unique position to lead this transformation for neuro-oncology in 2025 and beyond. Points to the imminent release of the new version of IB Clinic; its FDA-cleared suite of quantitative imaging solutions will include the incorporation of an AI model, which will greatly improve diagnostic accuracy and speed. In addition, notes the first half of 2025 should mark the next release of IB Nimble with the functionality to view IB's AI-generated images and other images within the mobile app. Also, in 2025 we anticipate releasing a new product leveraging arterial spin labelling. Read More

IN BRIEF: Braveheart buys 30% stake in IQ-AI from Braveheart CEO Brown

14th Oct 2024 10:05

IQ-AI Ltd - parent of Wisconsin-based Imaging Biometrics LLC, which provides quantitative imaging platforms and therapeutics for the diagnosis and treatment of patients - AIM-listed technology investor Braveheart Investment Group PLC buys a nearly 30% stake in IQ-AI from Braveheart Chief Executive Officer Trevor Brown. Braveheart buys 45.8 million IQ-AI shares from Brown at 1.1 pence per share, worth GBP503,372, and another 19.7 million shares owned by Brown's children at the same price, worth GBP216,203. The two purchases give Braveheart a 29.5% stake in IQ-AI. Braveheart on Friday says the related-party transaction is approved by its independent shareholders because the IQ-AI business fits Braveheart's investment strategy and the purchase is at "an attractive entry price". Read More

TRADING UPDATES: NetScientific loss narrows; Vinanz ups Bitcoin fleet

16th Aug 2024 20:40

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and Wednesday and not separately reported by Alliance News: Read More

IN BRIEF: IQ-AI subsidiary opens expanded access programme

25th Jun 2024 11:56

IQ-AI Ltd - London-based medical services company - US-based subsidiary Imaging Biometrics LLC says that US Food & Drug Administration has approved an expanded access programme for oral gallium maltolate. This EAP will run in parallel with the current phase 1 clinical trial being conducted at the Medical College of Wisconsin. Explains that "As the phase 1 trial concludes this fall and while the data is being compiled, eligible patients in the US will have the option of participating in the EAP." Read More

See more IQ-AI news
FTSE 100 Latest
Value8,582.81
Change-76.04

Login to your account

Forgot Password?

Not Registered